Ivonescimab In Combination With Chemotherapy Approved In China By NMPA For 2L+ Egfrm NSCLC Based On Harmoni-A Clinical ...
(MENAFN- PR Newswire) Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS …